Opko Health CEO Purchases $84,600 in Stock (OPK)
Opko Health (NYSE:OPK) CEO Phillip Md Et Al Frost bought 10,000 shares of Opko Health stock in a transaction that occurred on Monday, May 12th. The shares were purchased at an average cost of $8.46 per share, with a total value of $84,600.00. Following the acquisition, the chief executive officer now directly owns 1,987,500 shares in the company, valued at approximately $16,814,250. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
OPK has been the subject of a number of recent research reports. Analysts at Oppenheimer cut their price target on shares of Opko Health from $13.00 to $12.00 in a research note on Monday. They now have an “outperform” rating on the stock. Separately, analysts at Ned Davis Research upgraded shares of Opko Health from a “sell” rating to a “neutral” rating in a research note on Monday, April 28th. One equities research analyst has rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $12.50.
Opko Health (NYSE:OPK) opened at 8.41 on Tuesday. Opko Health has a 1-year low of $6.14 and a 1-year high of $12.95. The stock has a 50-day moving average of $8.6 and a 200-day moving average of $9.13. The company’s market cap is $3.410 billion. Opko Health also saw a large increase in short interest in April. As of April 30th, there was short interest totalling 50,337,366 shares, an increase of 6.2% from the April 15th total of 47,379,151 shares. Based on an average daily volume of 2,431,204 shares, the short-interest ratio is presently 20.7 days. Approximately 23.4% of the company’s stock are sold short.
Opko Health (NYSE:OPK) last announced its earnings results on Friday, May 9th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.10) by $0.01. The company had revenue of $22.30 million for the quarter, compared to the consensus estimate of $22.77 million. On average, analysts predict that Opko Health will post $-0.37 earnings per share for the current fiscal year.
OPKO Health, Inc (NYSE:OPK), incorporated in October 1991, is a multi-national pharmaceutical and diagnostics company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.